RWE and HTA: a snapshot of recent developments with Sreeram Ramagopalan – February–March 2021

Written by Sreeram Ramagopalan (F. Hoffmann-La Roche)
Cardiopulmonary and vascular Diabetes Guest columns Health technology assessment Industry Updates Journal articles Methodology Rare diseases and orphan drugs Real-world evidence

Read highlights from the latest instalment of Sreeram Ramagopalan’s (F. Hoffmann-La Roche, Basel, Switzerland) industry news round-up, which discusses some of the latest developments in real-world evidence (RWE) as it relates to health technology assessment (HTA) and acceptance of RWE by HTA agencies, and is published bi-monthly in our partner journal, the Journal of Comparative Effectiveness Research. The full update for February–March 2021, 'R WE ready for reimbursement?', is co-authored by Alex Simpson (F. Hoffmann-La Roche) and is now available to view online, here >>> What happened over these months that you were expecting? The first read-outs from the RCT...

To view this content, please register now for access

It's completely free